Merck: EC approves Keytruda in combination with trastuzumab

Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1. This approval allows marketing of this KEYTRUDA regimen in all 27 European Union member states plus Iceland, Lichtenstein, Norway and Northern Ireland.